KalVista CEO Sells Shares to Satisfy Tax Withholding as EKTERLY Drives Strong Revenue
KalVista Pharmaceuticals Chief Executive Officer Benjamin L. Palleiko sold 10,034 shares on February 23, 2026 to cover tax withholding obligations, realizing roughly $156,197. The company reported about $35 million in fourth-quarter 2025 revenue from its oral HAE treatment EKTERLY, contributing to approximately $49 million in full-year sales after …